LUM, lumican, 4060

N. diseases: 123; N. variants: 6
Disease: Cystic Fibrosis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 GeneticVariation disease BEFREE Lumacaftor/ivacaftor (LUM/IVA) improves outcomes in cystic fibrosis (CF) patients homozygous for Phe508del with ppFEV1 > 40%. 31848044 2019
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 GeneticVariation disease BEFREE In this study, we aimed to project long-term health outcomes of LUM/IVA plus standard care (SC) in patients with CF homozygous for F508del-CFTR. 30803355 2019
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 Biomarker disease BEFREE To compare CF pulmonary exacerbation rates before and after initiation of LUM/IVA in 1 state's Medicaid program. 31456498 2019
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 GeneticVariation disease BEFREE We report immediate post-dose respiratory-related adverse events in 12 patients with severe cystic fibrosis (CF) lung disease (median [IQR] ppFEV<sub>1</sub>: 34 [31-36]) prescribed LUM/IVA. 28314539 2017
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 Biomarker disease BEFREE Currently, LUM/IVA is the only oral agent in its class available and represents a milestone the development of therapies for the management of CF. 28891346 2017
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.060 Biomarker disease BEFREE The aim of the present study was to assess acute FEV<sub>1</sub> changes after the first dose of LUM/IVA in CF patients. 28529073 2017